Routine feasibility of postoperative chemoradiotherapy in head and neck squamous cell carcinoma at high risk of recurrence

Eur Ann Otorhinolaryngol Head Neck Dis. 2020 Nov;137(5):371-375. doi: 10.1016/j.anorl.2020.03.012. Epub 2020 Apr 11.

Abstract

Objective: To assess the feasibility in routine practice of postoperative chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence.

Method: A single-center retrospective study recruited all patients receiving postoperative cisplatin chemoradiotherapy for HNSCC at high risk of recurrence. The main endpoints were the rate of complete postoperative chemoradiotherapy and the impact of various clinical factors. Secondary endpoints comprised the impact of completion of therapy on survival and on acute and late toxicity.

Results: One hundred and six patients were included. 24.5% showed severe comorbidity. Chemoradiotherapy was complete in 61 patients (57.5%). Radiation therapy was interrupted for >3 days in 16 patients (15.1%). The 3rd concomitant cisplatin course could not be implemented in 34 patients (32.1%). Low pre-treatment glomerular filtration rate was significantly associated (p=0.003) with treatment interruption; >5% weight-loss during treatment showed suggestive association (p=0.026). Completion of treatment was not associated with any significant difference in overall survival (p=0.441) or progression-free survival (p=0.81). 14.9% of patients showed post-treatment kidney failure; there were 10 cases of osteoradionecrosis (9.4%).

Conclusion: The rate of complete postoperative chemoradiotherapy was comparable to that reported in clinical trials, despite frequent comorbidity and poor nutritional status. Early nutritional support is a key factor for treatment under optimal conditions.

Keywords: Adjuvant treatment; Advanced head and neck cancer; Postoperative chemoradiotherapy; Squamous cell carcinoma; Treatment interruption.

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Carcinoma, Squamous Cell* / drug therapy
  • Chemoradiotherapy
  • Feasibility Studies
  • Head and Neck Neoplasms* / drug therapy
  • Humans
  • Neoplasm Recurrence, Local / therapy
  • Retrospective Studies
  • Squamous Cell Carcinoma of Head and Neck / therapy

Substances

  • Antineoplastic Agents